A randomised phase II trial comparing docetaxel plus prednisone with docetaxel plus prednisone plus low-dose cyclophosphamide in castration-resistant prostate cancer - Abstract

Background: Docetaxel plus prednisone is a standard treatment for castration-resistant prostate cancer.

Cyclophosphamide may be an effective combination partner.

Methods: This randomised, multicentre, phase II trial compared the combination therapy of docetaxel plus prednisone plus cyclophosphamide with the standard therapy of docetaxel plus prednisone.

Results: Thirty-three patients received six 3-week treatment cycles (in total 171 cycles). During treatment, an adequate decline in prostate-specific antigen was seen in both groups (p = 0.068) without between-group differences (p = 0.683). No relevant differences between within-group changes were observed for blood pressure, weight, pain score, laboratory variables or quality of life. There were no serious side effects apart from leucopenia requiring treatment (docetaxel + prednisone + cyclophosphamide arm) and no drug-related withdrawals; all three fatalities were considered to be cancer related.

Conclusions: The oncological effectiveness and tolerability of docetaxel plus prednisone were supported; an additional effect of cyclophosphamide was not detected. However, the small number of patients and short observation period restrict the generalisability of the results.

Written by:
Porsch M, Ulrich M, Wendler JJ, Liehr UB, Reiher F, Janitzky A, Baumunk D, Schindele D, Seseke F, Lux A, Schostak M.   Are you the author?
Klinik für Urologie und Kinderurologie, Medizinische Fakultät, Otto-von-Guericke-Universität, Magdeburg, Germany.

Reference: Chemotherapy. 2015 Feb 26;60(2):129-134.
doi: 10.1159/000369781

PubMed Abstract
PMID: 25721356

UroToday.com Prostate Cancer Section